[1]
Deitelzweig S, Buysman E, Pinsky B, et al. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther 2013; 35: 1201-10.
[2]
Rodriguez R, Carrier M, Wells P. Non-adherence to new oral anticoagulants: A reason for concern during long-term anticoagulation? J Thromb Haemost 2013; 11: 390-4.
[3]
Chatterjee S, Sardar P, Giri J, Ghosh J, Mukherjee D. Treatment discontinuations with new oral agents for long-term anticoagulation: Insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clin Proc 2014; 89: 896-907.
[4]
Connolly S, Ezekowitz M, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
[5]
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
[6]
Miller C, Grandi S, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) Versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110: 453-60.
[7]
Maddox T, Ho P. Medication adherence and the patient with coronary artery disease: Challenges for the practitioner. Curr Opin Cardiol 2009; 24: 468-72.
[8]
Shore S, Carey E, Turakhia M, et al. Adherence to dabigatran and longitudinal patient outcomes: Insights from the veterans’ health administration. Am Heart J 2014; 167: 810-7.
[9]
Piccini J, Hernandez A, Zhao X, et al. Get with committee quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol 2009; 54: 1280-9.
[10]
Kneeland PP, Fang MC. Current issues in patient adherence and persistence: Focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010; 4: 51-60.
[11]
Wang Y, Kong M, Lee L, Ng HJ, Ko Y. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res 2014; 133: 550-4.
[12]
Ewen S, Rettig-Ewen V, Mahfoud F, Bohm M, Laufs U. Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol 2014; 103: 173-82.
[13]
D DiBonaventura M, Winnie W. Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation. Patient Prefer Adherence 2014; 8: 167-77.
[14]
Gadó K, Kocsis E, Zelkó R, et al. Drug compliance of patients on anticoagulant treatment. Orv Hetil 2015; 156: 1281-7.
[15]
Shantha GPS, Bhave PD, Girotra S, et al. Sex-specific comparative effectiveness of oral anticoagulants in elderly patients with newly diagnosed atrial fibrillation. Circ Cardiovasc Qual Outcomes 2017; 10: e003418.
[16]
Tsadok MA, Jackevicius CA, Rahme E, Humphries KH, Pilote L. Sex differences in dabigatran use, safety, and effectiveness in a population-based cohort of patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2015; 8: 593-9.
[17]
Almutairi AR, Zhou L, Gellad WF, et al. Effectiveness and safety of non–vitamin k antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: A systematic review and meta-analyses. Clin Ther 2017; 39: 1456-78.
[18]
Nielsen PB, Skjoth F, Sogaard M, Kjaeldgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study. BMJ 2017; 356: 510.
[19]
Emren SV, Şenöz O, Bilgin M, et al. Drug adherence in patients with nonvalvular atrial fibrillation taking non-vitamin K antagonist oral anticoagulants in Turkey: NOAC-TR. Clin Appl Thromb Hemost 2018; 24: 525-31.
[20]
Fuster V, Ryde’n L, Cannom D, et al. ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2011; 123: 269-7.
[21]
Jones C, Pollit V, Fitzmaurice D, Cowan C. The management of atrial fibrillation: Summary of updated NICE guidance. BMJ 2014; 348: 3655.
[23]
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomized trials. Lancet 2014; 383: 955-62.
[24]
Romanelli RJ, Nolting L, Dolgin M, Kym E, Orrico KB. Dabigatran versus warfarin for atrial fibrillation in real-world clinical practice: A systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2016; 9: 126-34.
[25]
Capranzano P, Micciche E, D’Urso L, Privitera F, Tamburino C. Personalizing oral anticoagulant treatment in patients with atrial fibrillation. Expert Rev Cardiovasc Ther 2013; 11: 959-73.
[26]
Pancholy S, Sharma P, Pancholy D, Patel T, Callans D, Marchlinski F. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol 2014; 113: 485-90.
[27]
Von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-9.
[28]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009; 339: 2700.
[29]
Gorst-Rasmussen A, Skjoth F, Larsen T, Rasussen L, Lip G, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: A nationwide cohort study. J Thromb Haemost 2015; 13: 495-504.
[30]
Hanemaaijer S, Sodihardjo F, Horikx A, et al. Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands. Int J Clin Pharm 2015; 37: 1128-35.
[31]
Yao X, Abraham N, Alexander C, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 2016; 5: e003074.
[32]
Beyer-Westendorf J, Forster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the dresden non-interventional oral anticoagulation registry. Europace 2015; 17: 530-8.
[33]
Luger S, Hohmann C, Niemann D, et al. Adherence to oral anticoagulant therapy in secondary stroke prevention- impact of the novel oral anticoagulants. Patient Prefer Adherence 2015; 9: 1695-705.
[34]
Shiga T, Naganuma M, Nagao T, et al. Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese population with atrial fibrillation: A single-center observational study. J Arrhythm 2015; 31: 339-44.
[35]
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
[36]
DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: An update. Contemp Clin Trials 2007; 28: 105-14.
[37]
Haidich A. Meta-analysis in medical research. Hippokratia 2010; 14(Suppl. 1): 29-37.
[38]
Ho PM, Bryson CL, Rumsfeld JS. Medication adherence its importance in cardiovascular outcomes. Circulation 2009; 119: 3028-35.
[39]
Kolandaivelu K, Leiden BB, O’Gara PT, Bhatt DL. Non-adherence to cardiovascular medications. Eur Heart J 2014; 35: 3267-76.
[40]
McHorney C, Crivera C, Laliberte F, et al. Adherence to non-vitamin K antagonist oral anticoagulant medications based on the pharmacy quality alliance measure. Curr Med Res Opin 2015; 31: 2167-73.
[42]
Brown J, Shewale A, Talbert J. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naïve nonvalvular atrial fibrillation. J Manag Care Spec Pharm 2016; 22: 1319-29.
[43]
Crivera C, Nelson W, Bookhart B, et al. Pharmacy quality alliance measure: Adherence to non-warfarin oral anticoagulant medications. Curr Med Res Opin 2015; 31: 1889-95.
[44]
Ewen S, Rettig-Ewen V, Mahfoud F, Bohm M, Laufs U. Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol 2014; 103: 173-82.
[45]
Thorne K, Jayathissa S, Dee S, et al. Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice. Intern Med J 2014; 44: 261-5.
[46]
Spivey C, Liu X, Qiao Y, et al. Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. Curr Med Res Opin 2015; 31: 2021-9.
[47]
Ruff C, Giugliano R, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomized trials. Lancet 2014; 383: 955-62.
[48]
Verdecchia P, Angeli F, Aita A, Bartolini C, Reboldi G. Why switching from warfarin to NOACs? Intern Emerg Med 2016; 11: 289-93.
[49]
Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): Predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014; 63: 2141-7.
[50]
Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran the RE-LY trial. Stroke 2012; 43: 1511-7.
[51]
Bayer-Westendorf J, Pannach S. Increase of gastrointestinal bleeding with new oral anticoagulants: Problem of a meta-analysis. Gastroenterology 2013; 145: 1162-3.
[52]
Chai-Adisakspha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: A systematic review and meta-analysis. Blood 2014; 124: 2450-8.
[53]
Larsen T, Rasmussen L, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world’ patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-73.
[54]
Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: Considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015; 17: 514-23.
